Beverage Giants Are Reformulating Hydration From The Gut Up. Are You?

Demand for personalised formulations, clean label ingredients, and plant-based options is now pulling hydration R&D in three directions that conflict with each other. Clean label conflicts with performance actives. Natural sourcing conflicts with stability. Plant-based conflicts with the amino acid and mineral profiles that underpin clinical efficacy. Managing all three simultaneously, in a single formulation, while building a clinical evidence base for health claims, is where most teams are stuck.

At the same time, the FDA changed the definition of “healthy” in 2024. Novel ingredients like marine algae fucoidan face multi-geography regulatory hurdles (EU Novel Food, FDA GRAS). The bar on functional claims is rising across the EU and the US, and the window to build clinical substantiation before regulators tighten further is not indefinitely open.

PepsiCo, Coca-Cola, Abbott, and Kenvue are already filing patents and running clinical trials on hyper-hydration and faster hydration mechanisms that will define this category for the next decade.

Four clusters are forming in the innovation landscape. This session maps each cluster by scientific maturity, ingredient availability, and competitive intensity, and identifies where the openings still are.

Five things you walk away with

1. Which innovation mechanisms have Coca-Cola and Pepsico already claimed?
2. Where do clinical nutrition companies like Abbott and Kenvue stand in this race?
3. Across the four active technology clusters in next-gen hydration, which ones still have room to move and which don’t? 
4. Which B2B ingredients can your team work with today, and which are still 2 to 3 years out? 
5. What are the regulatory realities of novel hydration actives across key markets?

If your formulation team is evaluating which innovation bets to make this year? Reserve your seat for the live session.